ライフサイエンスコーパス: locally advanced

1 n, is 11.7 months (95%CI 8.6-15.7 m, n = 15, locally advanced (2) and metastatic (13)).

2 patients undergoing neoadjuvant therapy for locally advanced adenocarcinoma, its value is unclear, l

3 Ninety-three patients had advanced stage (50 locally advanced and 43 metastatic) and 65 had lower sta

4 tasized to the liver, and many patients with locally advanced and metastatic disease show increases i

5 /24 (62.5%) and 27/31 (87%) of patients with locally advanced and metastatic disease, respectively.

6 rom the medical records of all patients with locally advanced and metastatic orbital or periocular BC

7 n combined with gemcitabine in patients with locally advanced and metastatic pancreatic cancer.

8 checkpoint inhibitor and/or chemotherapy in locally advanced and metastatic urothelial carcinoma.

9 sis of the R/M cSCC cohort from the 2-cohort-locally advanced and R/M-phase II KEYNOTE-629 study.

10 izumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urotheli

11 For patients with locally advanced and unresectable pancreatic cancer (PDA

12 ts with colorectal cancer are diagnosed with locally advanced and/or disseminated disease, and treatm

13 We enrolled patients with locally advanced and/or metastatic anaplastic thyroid ca

14 2 and 3 clinical trials for the treatment of locally advanced and/or metastatic breast cancer with ge

15 ry therapy for localized chondrosarcoma; for locally advanced and/or metastatic disease, no known eff

16 outcomes for a broad group of patients with locally advanced and/or node-positive tumors, it is less

17 erall survival (OS) benefit in patients with locally advanced and/or positive regional lymph node dis

18 nts, 46.4% were borderline resectable, 25.5% locally advanced, and 83.2% had pancreatic head/neck tum

19 disease: resectable, borderline resectable, locally advanced, and metastatic; patient condition is a

20 % of cases of kidney cancer are localized or locally advanced at diagnosis.

21 way inhibitor indicated for the treatment of locally advanced basal cell carcinoma (laBCC), with an o

22 Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also appro

23 years or older with borderline resectable or locally advanced biopsy-proven pancreatic ductal adenoca

24 se of adjuvant chemotherapy in patients with locally advanced bladder cancer postcystectomy who did n

25 ated with improved survival in patients with locally advanced bladder cancer.

26 Improvements in the treatment of locally advanced breast cancer (LABC) are needed.

27 ohort of ten patients with biopsy-confirmed, locally advanced breast cancer at the pre-treatment time

28 e analyzed DCE-MR images from 132 women with locally advanced breast cancer from the I-SPY1 trial to

29 The LABC (locally advanced breast cancer) group included 17 patien

30 marker discovery in other cancers (including locally advanced breast cancer, head and neck squamous c

31 diction of neoadjuvant treatment outcomes in locally advanced breast cancer.

32 All locally advanced breast cancers were (18)F-fluciclovine-

33 The study comprised 52 patients with locally advanced carcinoma, treated first with combined

34 lowing exenteration for recurrent sarcoma or locally advanced cervical cancer (3.3% each).

35 rapeutic intensification among patients with locally advanced cervical cancer (LACC) and paraaortic l

36 ains the standard treatment of patients with locally advanced cervical cancer (LACC), 40% of patients

37 o predict treatment failure in patients with locally advanced cervical cancer treated with chemo- and

38 cal control for many malignancies, including locally advanced cervical cancer, head and neck cancer,

39 ckade may be a viable therapeutic option for locally advanced cSCC and provides rationale for further

40 A single patient with locally advanced cSCC who declined surgery and radiother

41 In 1 patient with locally advanced cSCC who was treated with pembrolizumab

42 d cell death 1 receptor (PD-1) inhibitors in locally advanced cSCC.

43 treatment, according to their perception as locally advanced (cT3) or early-stage tumors (stage II).

44 Patients and Methods Patients with locally advanced (cT3-4 or cN+) rectal cancer who were t

45 es are available in patients with inoperable locally advanced cutaneous squamous cell carcinoma (cSCC

46 ged >=18 years with histologically confirmed locally advanced cutaneous squamous cell carcinoma and a

47 n acceptable safety profile in patients with locally advanced cutaneous squamous cell carcinoma for w

48 Patients with locally advanced cutaneous squamous cell carcinoma have

49 mour activity of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma.

50 Following explorative laparoscopy, locally advanced diffuse gastric cancer was diagnosed.

51 tients with resected localized high-grade or locally advanced disease (>= pT1b grade 3 and 4/pTanyN1M

52 e >= 70 years: 67.5% v 60.9%), fewer men had locally advanced disease (56.5% v 71.3%), were less like

53 s according to the types of HCC progression: locally advanced disease (LAD), extrahepatic disease (EH

54 entified 11 trials of docetaxel for men with locally advanced disease (M0).

55 Patients with locally advanced disease (T3/T4) presented with more sym

56 on of targeted agents into the management of locally advanced disease and the timing of radiotherapy

57 nts with pancreatic cancer have unresectable locally advanced disease at diagnosis.

58 disease, whereas patients with patients with locally advanced disease receive perioperative chemother

59 with metastases and 11 patients [6.0%] with locally advanced disease) at the National Institutes of

60 s multimodal therapy containing platinum for locally advanced disease, were randomly assigned (1:1) i

61 r patients is increasing beyond the scope of locally advanced disease.

62 esophagectomy is indicated for patients with locally advanced disease.

63 rrence after treatment remain significant in locally advanced disease.

64 on and weight loss have predictive value for locally advanced disease.

65 ts with PDAC; 31 with metastatic and 24 with locally advanced disease.

66 eived neoadjuvant chemotherapy for localized/locally advanced disease; 51 received chemotherapy for u

67 ss treatment-related toxicity for women with locally-advanced disease.

68 se, we reviewed 97 consecutive patients with locally advanced EC and a pretreatment (18)F-FDG PET/CT

69 se, we reviewed 97 consecutive patients with locally advanced EC and a pretreatment (18)F-FDG PET/CT

70 step in predicting tumor response to nCRT in locally advanced EC.

71 calized (equivalent to primary stages I-II), locally advanced (equivalent to primary stages III-IVB),

72 his retrospective study of 184 patients with locally advanced ESCC.

73 imizes staging and survival in patients with locally advanced esophageal adenocarcinoma (EAC) treated

74 tients who underwent trimodality therapy for locally advanced esophageal adenocarcinoma between 1995

75 f sarcopenia in the multimodal management of locally advanced esophageal cancer (LAEC), and to assess

76 icting complete pathologic response (pCR) in locally advanced esophageal cancer (LAEC).

77 9-2019) on therapy options for patients with locally advanced esophageal cancer and provide recommend

78 improved overall survival for patients with locally advanced esophageal cancer, and to evaluate how

79 ence treatment and outcomes of patients with locally advanced esophageal cancer.

80 chemoradiation and surgery in patients with locally advanced esophageal cancer.

81 Multimodality therapy for patients with locally advanced esophageal carcinoma is recommended.

82 ) of imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs).

83 adiotherapy (CRT) for patients with resected locally advanced head and neck cancer (LAHNC) with negat

84 nce every 3 weeks is the standard of care in locally advanced head and neck squamous cell cancer (LAH

85 apy, a standard of care for the treatment of locally advanced head and neck squamous cell cancers.

86 of response to radiotherapy and cetuximab in locally advanced head and neck squamous cell carcinoma (

87 ent response to radical chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (

88 X-ray dose delivered over several weeks for locally advanced head and neck tumors).

89 underwent left nephroureterectomy, revealing locally advanced high-grade UC invading the renal parenc

90 ents receiving definitive chemoradiation for locally advanced HNSCCs underwent pretherapeutic biopsie

91 Twenty-seven women with a new diagnosis of locally advanced IDC (n = 19) or ILC (n = 8) underwent P

92 medical clinics, treatment-naive adults with locally advanced, inflammatory, or early-stage HER2-posi

93 eptor-positive, HER2-negative, metastatic or locally advanced inoperable breast cancer who had relaps

94 rbed dose and survival and tumor response in locally advanced inoperable hepatocellular carcinoma tre

95 Women who have large or locally advanced invasive breast cancer (tumor size T3/T

96 Twenty-four women with a new diagnosis of locally advanced invasive ductal breast cancer (n = 18)

97 s: Twenty-four women with a new diagnosis of locally advanced invasive ductal breast cancer (n = 18)

98 inoma (HNSCC), its role in the management of locally advanced (LA) disease is not defined.

99 patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (

100 ectability of borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (

101 immunotherapy could change the perception of locally advanced lung cancer as a potentially lethal dis

102 ulin may be efficacious for the treatment of locally advanced/MBC for patients with bone, liver, lung

103 at baseline in 1864 pretreated patients with locally advanced/MBC from studies 301 and 305.

104 ibulin appeared efficacious in patients with locally advanced/MBC, irrespective of the location of me

105 The discovery of a locally advanced medullary thyroid cancer that is not am

106 It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cance

107 onged overall survival (OS) in patients with locally advanced/metastatic breast cancer (MBC) regardle

108 sparing treatment paradigm for patients with locally advanced MPM.

109 atients with borderline resectable (n = 18), locally advanced (n = 190), or oligometastatic (n = 72)

110 annually worldwide present with localised or locally advanced non-metastatic disease.

111 ed cardiac toxicity studies in patients with locally advanced non-small cell lung cancer (NSCLC) have

112 oxic effects in the definitive management of locally advanced non-small cell lung cancer (NSCLC), but

113 patients treated with chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC).

114 nts undergoing radiotherapy for nonoperative locally advanced non-small cell lung cancer between 2004

115 therapy (IMRT) is increasingly used to treat locally advanced non-small-cell lung cancer (NSCLC), IMR

116 nt FDG-PET to improve local tumor control of locally advanced non-small-cell lung cancer (NSCLC).

117 modality treatment of patients with operable locally advanced non-small-cell lung cancer.

118 perioperative chemotherapy in patients with locally advanced nonmetastatic CC.

119 Eligible patients had locally advanced NSCLC and no contraindication to concom

120 study compares 3D-CRT and IMRT outcomes for locally advanced NSCLC in a large prospective clinical t

121 rospective analysis included 748 consecutive locally advanced NSCLC patients treated with thoracic ra

122 e competing risk of cancer-specific death in locally advanced NSCLC patients, cardiac radiation dose

123 diac events exceeded 10% among patients with locally advanced NSCLC treated with definitive radiation

124 Patients with locally advanced NSCLC underwent (18)F-FDG PET prior to

125 0617, which supports routine use of IMRT for locally advanced NSCLC.

126 ts aged 18 years or older with metastatic or locally advanced NTRK fusion-positive solid tumours who

127 upplemented surgery as standard treatment of locally advanced oesophageal cancer.

128 uvant concurrent chemoradiotherapy (CRT) for locally advanced or incompletely resected non-small-cell

129 dotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours k

130 confirmed EGFR Thr790Met-positive mutations, locally advanced or metastatic (stage IIIB/IV) NSCLC who

131 or progesterone receptor-positive, or both, locally advanced or metastatic breast cancer from 113 ac

132 rs or older with HER2-positive unresectable, locally advanced or metastatic breast cancer previously

133 for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have no

134 mal growth factor (HER2)-negative inoperable locally advanced or metastatic breast cancer whose disea

135 ed hormone-receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, who had re

136 andard of care for hormone receptor-positive locally advanced or metastatic breast cancer.

137 e aged 18 years or older with ALK-rearranged locally advanced or metastatic cancer that had progresse

138 ctively collected data from 51 patients with locally advanced or metastatic cancer undergoing treatme

139 t patients (aged >/=18 years) diagnosed with locally advanced or metastatic carcinoma of the pancreas

140 Patients and Methods Eligible patients had locally advanced or metastatic ccRCC that had progressed

141 gatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with a

142 f first-line pembrolizumab for patients with locally advanced or metastatic cisplatin-ineligible urot

143 nts aged at least 18 years with unresectable locally advanced or metastatic colorectal cancer, baseli

144 DAC is mostly diagnosed late, when already a locally advanced or metastatic disease, as there are no

145 ans were obtained in 21 patients with either locally advanced or metastatic disease.

146 hs worldwide, and most patients present with locally advanced or metastatic disease.

147 ears or older with histologically confirmed, locally advanced or metastatic epithelioid sarcoma; docu

148 d moderate survival duration in unresectable locally advanced or metastatic esthesioneuroblastoma war

149 adults (aged >/=18 years) with unresectable locally advanced or metastatic gastric or gastro-oesopha

150 patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusi

151 ended as first-line therapy to patients with locally advanced or metastatic non-small-cell lung cance

152 dults (>=18 years) with previously untreated locally advanced or metastatic non-small-cell lung cance

153 nt naive or previously treated patients with locally advanced or metastatic non-small-cell lung cance

154 tients aged 18 years or older with confirmed locally advanced or metastatic NSCLC.

155 for stratifying and monitoring patients with locally advanced or metastatic pancreatic ductal adenoca

156 thods Patients with histologically confirmed locally advanced or metastatic PRCC were enrolled and re

157 It recruits men with high-risk, locally advanced or metastatic prostate cancer who were

158 Among men with locally advanced or metastatic prostate cancer, ADT plus

159 ored the use of entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive NSCL

160 cluded adult patients (aged >=18 years) with locally advanced or metastatic ROS1 fusion-positive NSCL

161 For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has b

162 had a histologically confirmed diagnosis of locally advanced or metastatic soft-tissue sarcoma not p

163 igible patients had histologically confirmed locally advanced or metastatic soft-tissue sarcoma of Tr

164 ents when selecting first-line treatment for locally advanced or metastatic soft-tissue sarcoma.

165 in Belgium, the Netherlands, and the UK with locally advanced or metastatic solid tumours with variab

166 years or older with measurable, inoperable, locally advanced or metastatic triple-negative breast ca

167 ab-paclitaxel in patients with unresectable, locally advanced or metastatic triple-negative breast ca

168 iously untreated, histologically documented, locally advanced or metastatic triple-negative breast ca

169 recruited previously untreated patients with locally advanced or metastatic urothelial cancer who wer

170 ally or cytologically confirmed diagnosis of locally advanced or metastatic urothelial cancer, includ

171 PD-1 antibody pembrolizumab in patients with locally advanced or metastatic urothelial cancer.

172 udy that includes patients with unresectable locally advanced or metastatic urothelial carcinoma (mUC

173 Few options exist for patients with locally advanced or metastatic urothelial carcinoma afte

174 Locally advanced or metastatic urothelial carcinoma is a

175 erapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is a

176 nd point for prolonging PFS in patients with locally advanced or metastatic urothelial carcinoma rece

177 th histologically or cytologically confirmed locally advanced or metastatic urothelial carcinoma that

178 d 15 of every 28-day cycle) in patients with locally advanced or metastatic urothelial carcinoma who

179 nd tolerable safety profile in patients with locally advanced or metastatic urothelial carcinoma who

180 b vedotin in December 2019 for patients with locally advanced or metastatic urothelial carcinoma who

181 ity and safety of nivolumab in patients with locally advanced or metastatic urothelial carcinoma whos

182 patients (aged >/=18 years) with inoperable locally advanced or metastatic urothelial carcinoma whos

183 al in patients with untreated, unresectable, locally advanced or metastatic urothelial carcinoma, con

184 treated patients aged 18 years or older with locally advanced or metastatic urothelial carcinoma, fro

185 2020 for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

186 expanded treatment options for patients with locally advanced or metastatic urothelial carcinoma.

187 profile in previously treated patients with locally advanced or metastatic urothelial carcinoma.

188 of platinum-based regimens for patients with locally advanced or metastatic urothelial carcinoma.

189 er with histologically proven, unresectable, locally advanced or metastatic, HER2-positive, PD-L1-uns

190 rolled adult patients (aged >=18 years) with locally advanced or metastatic, MET-amplified, EGFR muta

191 For most sarcomas, locally advanced or unresectable disease is still treate

192 aive, histologically confirmed metastatic or locally advanced (or both) clear-cell renal cell carcino

193 e status of 0 or 1, HER2-positive, operable, locally advanced, or inflammatory stage II-IIIC breast c

194 ious chemotherapy regimens for unresectable, locally advanced, or metastatic disease (0 or 1 vs >1),

195 ressively worsened prognosis with localized, locally advanced, or metastatic disease (log-rank test,

196 the survival courses of patients with local, locally advanced, or metastatic disease and predict thei

197 itive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric cancer, includin

198 AF(V600E)-mutated, unresectable, metastatic, locally advanced, or recurrent biliary tract cancer, an

199 of 223 patients (from 44 institutions) with locally advanced oral cavity or oropharynx cancer planne

200 In a specialized setting, P-AR for locally advanced pancreatic adenocarcinoma can be perfor

201 y for patients with borderline resectable or locally advanced pancreatic adenocarcinoma.

202 ic benefits have limited the use of P-AR for locally advanced pancreatic adenocarcinoma.

203 roporation was exceeded in participants with locally advanced pancreatic cancer (17 months) and those

204 Meier method was 17 months from diagnosis of locally advanced pancreatic cancer (95% confidence inter

205 as to identify the survival of patients with locally advanced pancreatic cancer (LAPC) and assess the

206 ferences for the management of patients with locally advanced pancreatic cancer (LAPC).

207 2015, 25 patients with histologically proved locally advanced pancreatic cancer 5 cm or smaller (13 w

208 neous irreversible electroporation (IRE) for locally advanced pancreatic cancer and (b) evaluate the

209 [interquartile range, 56-69 years]; 40 with locally advanced pancreatic cancer and 10 with local rec

210 safety and efficacy of percutaneous IRE for locally advanced pancreatic cancer and locally recurring

211 In the locally advanced pancreatic cancer group, 18 participant

212 Background Patients with locally advanced pancreatic cancer have a dismal prognos

213 Conclusion Percutaneous IRE for locally advanced pancreatic cancer is generally well tol

214 atients who underwent surgical resection for locally advanced pancreatic cancer ranged from 0% to 43%

215 Patients with locally advanced pancreatic cancer treated with FOLFIRIN

216 Thirty-four patients with locally advanced pancreatic cancer were enrolled with th

217 el, randomized trial involving patients with locally advanced pancreatic cancer with disease controll

218 In locally advanced pancreatic cancer, the role of chemorad

219 d radiation in patients with newly diagnosed locally advanced pancreatic cancer.

220 nique, may prolong survival of patients with locally advanced pancreatic cancer.

221 689 patients, of whom 355 (52%) patients had locally advanced pancreatic cancer.

222 ceived FOLFIRINOX as first-line treatment of locally advanced pancreatic cancer.

223 irinotecan and oxaliplatin) in patients with locally advanced pancreatic cancer.

224 lying a biologic basis for presentation with locally advanced pancreatic cancer.

225 l therapies in highly selected patients with locally advanced PC, following a prolonged period of ind

226 nt chemotherapy in borderline-resectable and locally advanced PDAC RESULTS:: In the retrospective coh

227 f 331 patients with borderline resectable or locally advanced PDAC, 30 achieved a pCR following neoad

228 n a phase II randomized controlled trial for locally advanced PDAC.

229 gest study to date on vismodegib therapy for locally advanced periocular BCC.

230 Group performance status 0-1, metastatic or locally advanced previously treated solid tumours, and a

231 ions that include cancer stem-like cells, in locally advanced primary and metastatic TNBC.

232 egarding the role of pelvic exenteration for locally advanced primary rectal cancer (LARC).

233 Patients with locally advanced prostate cancer have an increased risk

234 ng PLNs in radiation fields for high-risk or locally advanced prostate cancer is not associated with

235 eoadjuvant hormone therapy followed by RP in locally advanced prostate cancer resulted in favorable p

236 Patients with high-risk localized or locally advanced prostate cancer treated with IMRT in th

237 for the treatment of men with localized and locally advanced prostate cancer, and those with oligome

238 efore radical prostatectomy (RP) in men with locally advanced prostate cancer.

239 on treatment is a viable option for treating locally advanced prostate cancer.

240 intermediate-risk or high-risk, localised or locally advanced prostate cancer.

241 treatment option for men with localized and locally advanced prostate cancer.

242 event-free survival in men with localised or locally advanced prostate cancer.

243 priate for men who present with localised or locally advanced prostate cancer.

244 In the PRT setting of locally advanced RC, SRCC patients had significantly wor

245 abase identified patients with nonmetastatic locally advanced rectal adenocarcinoma from 2010 to 2014

246 Patients with locally advanced rectal adenocarcinoma were treated with

247 a living organoid biobank from patients with locally advanced rectal cancer (LARC) treated with neoad

248 he cornerstone for the curative treatment of locally advanced rectal cancer (LARC).

249 ently associated with a reduction in pCR for locally advanced rectal cancer after neoadjuvant chemora

250 to concomitant neoadjuvant chemoradiation in locally advanced rectal cancer could increase pathologic

251 The standard of care in locally advanced rectal cancer is preoperative, long cou

252 mor volume (WTV) methods in 62 patients with locally advanced rectal cancer on pre- and post-CRT imag

253 eatment planning CT can predict prognosis in locally advanced rectal cancer patients treated with neo

254 Four-hundred-eleven locally advanced rectal cancer patients which were treat

255 diotherapy CT can potentially predict OS for locally advanced rectal cancer patients with neoadjuvant

256 , T2-weighted, and DWI) of 140 patients with locally advanced rectal cancer were included in our anal

257 zed 5086 patients between 2010 and 2015 with locally advanced rectal cancer who were tested for MSI a

258 py followed by total mesorectal excision for locally advanced rectal cancer, patients who experience

259 vival in patients with MRI-defined high-risk locally advanced rectal cancer.

260 the preoperative treatment of patients with locally advanced rectal cancer.

261 ted with a survival benefit in patients with locally advanced rectal cancer.

262 are needed to improve chemoradiotherapy for locally advanced rectal cancer.

263 rd chemoradiation is needed in patients with locally advanced rectal cancer.

264 l excision (TME) is the standard of care for locally advanced rectal cancer.

265 tment responders during preoperative CRT for locally advanced rectal cancer.

266 fter preoperative chemoradiotherapy (CRT) in locally advanced rectal cancer.

267 tcomes of total neoadjuvant therapy (TNT) on locally advanced rectal cancer.

268 bine improves disease-free survival (DFS) in locally advanced rectal cancer.

269 eoadjuvant radiation is standard of care for locally advanced rectal cancer.

270 ffect of preoperative radiotherapy (PRT) for locally advanced rectal SRCC in a large patient group fr

271 ve advanced breast cancer with unresectable, locally advanced, recurrent or metastatic disease, Easte

272 ed anonymously from individual patients with locally advanced, recurrent or metastatic TGCT.

273 Perioperative FOLFOX for locally advanced resectable CC is feasible with an accep

274 nd were newly diagnosed with stage II to III locally advanced, resectable adenocarcinoma of the rectu

275 nce of metastatic or surgically unresectable locally advanced sarcoma, had received up to three previ

276 Adults (aged >=18 years) with locally advanced soft-tissue sarcoma of the extremity or

277 s a pre-operative treatment in patients with locally advanced soft-tissue sarcoma.

278 atumoral chemo-radio combination therapy for locally advanced solid tumors.

279 fety analysis of patients with metastatic or locally advanced solid tumours harbouring oncogenic NTRK

280 t cetuximab (CTX) as first-line treatment of locally advanced squamous cell carcinoma of the head and

281 er (NSCLC) is terminal in most patients with locally advanced stage disease.

282 s require some form of palliation because of locally advanced stage or distant metastasis, where it c

283 categorized as localized (stages I and II), locally advanced (stages III and IVB), or metastatic (st

284 For patients with locally advanced (T3, T4) disease, organ-preservation su

285 In the Phase II locally-advanced trial (NCI# 01821729) cohort of 34 pati

286 tient-derived xenograft (PDX) engraftment in locally advanced tumors (T3-T4 or N+) predict poor progn

287 Notably, MCAM and LAMA4 were enhanced in locally advanced tumors as well as both the primary tumo

288 ssible impact of neoadjuvant pretreatment in locally advanced tumors should be considered with cautio

289 For some locally advanced tumors, chemoradiation is currently sta

290 w, be a better strategy for treating certain locally advanced tumors.

291 py with trastuzumab plus chemotherapy in the locally advanced unresectable or metastatic setting.

292 ficacy of radiation therapy in patients with locally advanced unresectable PDA have reported mixed re

293 al in patients with borderline resectable or locally advanced unresectable PDAC receiving SOC neoadju

294 nefit patients with borderline resectable or locally advanced unresectable PDAC.

295 al of patients with borderline resectable or locally advanced unresectable PDAC.

296 ed in randomized controlled trials involving locally advanced, unresectable pancreatic cancer.

297 ith single-drug doxorubicin in patients with locally advanced, unresectable, or metastatic soft-tissu

298 r with metastatic or surgically unresectable locally advanced urothelial carcinoma, measurable diseas

299 roved disease-free survival in patients with locally advanced UTUC.

300 .06; 95% CI, 1.09-3.91; P = .027) and stage (locally advanced vs resectable or borderline: HR, 1.66;